Production
Completed in 2012, the L House Vaccine Center is the largest cell culture vaccine factory in Korea.
Optimization of mass manufacture and distribution of vaccines through Korea’s largest facility and specialized technology
Capabilities
SK bioscience boasts the highest cost efficiency with its technological expertise and state-of-the-art facilities.

Versatility - Bacterial Suites, Viral Suites, Fill & Finish
- Bacterial Suites : PCV, TCV, MCV/MenB
- Viral Suites : cFlu, Zoster, Varicella, HPV, Rota, NRRV
- Fill & Finish : PFS, (single, multi), Oral drop, Freeze-dry
Pioneer in successful adaptation of ‘single-use system’ for vaccines on commercial scale
- 1. Flexibility using single-use system
- Speed of execution for process development & scale-up
- Cost effectiveness due to quick turnaround time, easy validation, and reduced cleaning requirements
- 2. Diverse platforms
- Diverse vaccine production in a suite
- Flexible & rapid supply of clinical materials and commercial products
- 3. Future expansion
- Rapid expansion for capacity increase
‘Multi-modular system’ for diverse vaccine types
Fermentation
- E coli/yeast
- Polysaccharide
Protein conjugate
- DT/CRM197/TT
Cell culture
- Suspension
- Adherent
- Microcarrier
Recombination
- Commercial
- SKYCellflu
- SKYZoster
- SKYVaricella
- SKYCovione
- In-house R&D
- HPV
- Oral Rota
- Next PCV
- COVID 19
- Sarbecovirus
- Partnership R&D
- TCV
- NRRV
- COVID 19
- Sarbecovirus